These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19929712)

  • 21. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
    Wandeler G; Furrer H; Rauch A
    AIDS; 2011 Nov; 25(18):2306-8. PubMed ID: 22067200
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
    Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
    J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
    Ratcliffe L; Beadsworth MB; Pennell A; Phillips M; Vilar FJ
    AIDS; 2011 May; 25(8):1051-6. PubMed ID: 21346511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 27. Trial will evaluate a once-daily dose of raltegravir.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
    Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
    Antivir Ther; 2011; 16(4):499-504. PubMed ID: 21685537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Avit D; Kruy LS; McIntyre J; Say L; Gray G; Ekouévi DK; Dabis F
    AIDS; 2010 Oct; 24(16):2481-8. PubMed ID: 20827166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
    van de Vijver DA; Boucher CA
    Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
    Psevdos G; Gonzalez E; Sharp V
    AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 38. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 40. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.